PRIMROSE THERAPEUTICS

Primrose Therapeutics, Inc. is a biotechnology company focused on the development of treatments for Polycystic Kidney Disease (PKD). PKD is one of the most common life-threatening genetic disorders, affecting 600,000 Americans and 12.5 million people worldwide -- more than cystic fibrosis, muscular dystrophy, hemophilia, Down syndrome and sickle cell anemia combined. PKD results in the abnormal growth of cells in the kidney, which eventually lead to the development of bilateral kidney cysts and structural destruction of the kidney. The average lifespan of PKD patients is 64 years -- at least a decade shorter than average. No FDA approved therapies currently exist for this devastating disease.